References
- Milano G, Etienne M-C. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review). Anti-cancer Res 1994; 14: 2295–2298
- Lu Z, Zhang R, Diasio R B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics. newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53: 5433–5438
- Sommadossi J-P, Gerwirtz D A, Diasio R B, et al. Rapid catabo-lism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography. J Biol Chem 1982; 257: 8171–8176
- Fleming R, Milano G, Thyss A, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992; 52: 2899–2902
- Tuchman M, Stoeckeler J S, Kiang D T, et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 1985; 313: 245–249
- Diasio R B, Beavers T L, Carpenter J T. Familial deficiency of dihydropyrimidine dehydrogenase. J Clin Invest 1988; 81: 47–51
- Riebl J-L, Brown W J. Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology 1964; 961–967
- Lynch H T, Droszcz C P, Albano W A, et al. “Organic brain syndrome” secondary to 5-fluorouracil toxicity. Dis Colon Rectum 1981; 24: 130–131
- Hook C C, Kimmel D W, Kvols L K, et al. Multifocal inflammatory leukoencephaiopathy with 5-fluorouracil and levamisole. Ann Neurol 1992; 31: 262–267
- Fassas AE-T, Gattani A M, Morgello S. Cerebral demyelination with 5-fluorouracil and levamisole. Cancer Invest 1994; 12: 379–383
- Takimoto C H, Lu Z, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996; 2: 477–481
- Fleming R A, Milano G A, Gaspard M H, et al. Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 1993; 29A: 740–744
- Bourke R S, West C R, Chheda G, et al. Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res 1973; 33: 1735–1746
- Stephan F, Etienne M-C, Wallahs C, et al. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am J Med 1995; 99: 685–688
- Chainage H, Panel A. Biochemical basis of the acute cerebellar syndrome in 5-fluorouracil chemotherapy. Trans Am Neurol Assoc 1969; 94: 290–292
- Harris B E, Carpenter J T, Diasio R B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. Cancer 1991; 68: 499–501
- Etienne M C, Lagrange J L, Dassonville O, et al. Population study of dihydropyrirnidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248–2253
- Milano G, Etienne M-C. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Phamiacogen 1994; 4: 301–306
- Daher G C, Naquib F N, el-Kouni M H, et al. Inhibition of fluoro-pyrimidine catabolism by benzyloxybenzyluracil. Possible relevance to regional chemotherapy, Biochem Pharmacol 1991; 41: 1887–1893
- Spector T, Cao S, Rustum Y M, et al. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5.6-dihydrouracil. Cancer Res 1995; 55: 1239–1241
- Baccanari D P, Davis S T, Knick V C, et al. (776C85): a potent modulator of the pharmac and antitumor efficacy of 5-fluorouracil. Roc Natl Acad Sci USA 1993; 90: 11064–11068
- Cao S, Rustum Y M, Spector T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994; 54: 1507–1510
- Rowinsky E K, Baker S D. The dihydropyrimidine dehydrogenase inhibitor 776C 85, making oral 5-fiuorouracil practical and modifying its therapeutic index. Cancer Invest 1996; 15(Suppl 1)16–18
- Lu Z, Zhang R, Diasio R B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res, 53: 5433–5438